NC
VTYX

NinePointTwo Capital’s Ventyx Biosciences VTYX Stock Holding History

NinePointTwo Capital’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,741
Closed -$253K – 331
2023
Q2 		$253K Buy
+7,741
New +$267K 0.1% 130

Other funds holding VTYX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

NinePointTwo Capital's VTYX Position: Q3 2023 in Review

NinePointTwo Capital sold out of Ventyx Biosciences (VTYX) in Q3 2023, closing a stake of 7,741 shares — an estimated $253K sold.

NinePointTwo Capital first reported a position in VTYX in Q2 2023 and held it in 1 quarter. The position peaked at $253K in Q2 2023. 138 funds tracked by Wall St. Rank hold VTYX as of Q3 2023.

  • NinePointTwo Capital reported no remaining Ventyx Biosciences position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 7,741 Ventyx Biosciences shares in Q3 2023, an estimated $253K.
  • NinePointTwo Capital first reported a position in Ventyx Biosciences in Q2 2023 and held it in 1 quarter.
  • NinePointTwo Capital's Ventyx Biosciences position peaked at $253K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.